CytomX Therapeutics To Present Preclinical Data For Conditionally Activated Interferon Alpha-2b At The SITC 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced that it will present preclinical data for its conditionally activated cytokine program, CX-801, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The company anticipates filing an IND for CX-801 by the end of 2023.
October 30, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytomX Therapeutics is set to present preclinical data for its CX-801 program at the SITC Annual Meeting, with an IND filing expected by the end of 2023.
The announcement of the presentation of preclinical data for CX-801 at a major conference is a positive development for CytomX Therapeutics. This suggests that the company is making progress in its research and development efforts. The anticipation of an IND filing by the end of 2023 also indicates that the company is moving forward with its regulatory processes. Both of these factors could have a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100